Glow Peptides · Research Journal

Peptide Synthesis and Purity: SPPS vs Liquid-Phase Explained

Glow Peptides Research Team · 2026-04-07

For research use only. Not for human or veterinary use, diagnostic use, or in any therapeutic application.

A purity figure is not a property of a peptide. It is the result of a measurement made on the output of a particular manufacturing route, and the route determines which impurities are there to be measured. Understanding how a peptide was built — solid-phase, solution-phase, or a hybrid — tells you what the leftover material is likely to be, why it is there, and what a number like ≥99.2% on a published certificate is actually counting. This guide walks the chemistry, then connects it to what you can read off a document.

If you want the shorter reference on the instruments rather than the synthesis, the guide on HPLC and mass spectrometry covers how each method works and what each one answers. This page is about what happens before the sample reaches either instrument.

Why the synthesis route decides what a purity number means

Two vials can carry certificates reporting the same purity percentage and contain materially different things. The percentage tells you what proportion of detected material was the target compound. It does not tell you what the remainder was. And the remainder is not random: it is a predictable consequence of how the chain was assembled, what protected the reactive groups along the way, what cleaved it off its support, and what was done to clean it up afterwards.

Impurities in a synthetic peptide are not contamination in the ordinary sense. They are chemistry. Every step has an efficiency below one hundred per cent, and material that fails to react correctly does not disappear. It carries forward as a closely related molecule that has to be separated out later, or accepted as part of the impurity profile.

So the sequence runs: route determines the impurity classes, the impurity classes determine what purification has to remove, and the purification determines what is left for the analysis to find. A purity number sits at the end of that chain.

Solid-phase peptide synthesis, step by step

Solid-phase peptide synthesis (SPPS) was developed by Robert Bruce Merrifield in 1963, work for which he received the Nobel Prize in Chemistry in 1984. It is the dominant route for research peptides today, and the reason is practical: it makes the tedious part of the job — separating the growing product from everything else after each step — almost trivial.

The cycle

The peptide is built from the C-terminus backwards, anchored throughout to an insoluble polymer bead. Because the product is attached to something that can be filtered and washed, every reagent and by-product from a step is rinsed away without a purification in the usual sense.

1. Resin attachment. The C-terminal amino acid is anchored to a polymer resin bead through a linker. The choice of linker determines what the C-terminus looks like after cleavage — a free acid or an amide.
2. Deprotection. The temporary protecting group on the N-terminus is removed, exposing the amine that will form the next bond.
3. Coupling. The next amino acid, carboxyl group activated and side chain protected, is added in excess and forms an amide bond with that amine.
4. Wash. Excess reagent and by-products are filtered away. The product stays on the bead.
5. Repeat. Steps 2 to 4 run once per residue.
6. Cleavage. The finished chain is released from the resin and side-chain protecting groups are removed, typically with a strong acid cocktail.
7. Purification. The crude is separated by preparative reverse-phase HPLC, the target fraction collected, then lyophilised.

Where the cycle leaks

The arithmetic of a repeated cycle is unforgiving. If each coupling step went to 99 per cent completion, a twenty-residue peptide would finish with roughly 82 per cent of chains intact. At 99.5 per cent per step it would be around 91 per cent. Real syntheses are more complicated than a single average efficiency, but the shape of the problem is exactly that. Small per-step losses compound into a crude mixture where the target is one component among many closely related ones.

Two further difficulties scale with length. Longer chains can aggregate while still on the resin, folding against each other so the reactive end is physically less available, which drives coupling efficiency down where you can least afford it. And each additional cycle is another opportunity for a side reaction on a sensitive residue. Sequence length and composition, not brand or price, are the strongest predictors of how hard a peptide is to make well.

Fmoc and Boc: two protecting-group strategies

The temporary N-terminal protecting group has to come off cleanly at every cycle without disturbing the side-chain protection or the linker. Two strategies dominate, differing in the chemistry used to remove it.

Fmoc became the default for three reasons that all matter to purity. The deprotection conditions are mild, so the growing chain meets strong acid only once, at the end, rather than at every cycle. The released protecting group absorbs ultraviolet light, so a synthesiser can watch each deprotection go to completion and flag a step that did not. And the handling requirements are far less demanding than anhydrous hydrogen fluoride.

Boc chemistry has not vanished. Repeated acid treatment disrupts on-resin aggregation, so for sequences that stall badly under Fmoc conditions the older route still gives a better crude. The point is not that one route is superior, but that the route is a choice with consequences, and the consequences show up in the impurity profile.

Liquid-phase synthesis, and when it is the right tool

Liquid-phase peptide synthesis — also called solution-phase — performs the same bond-forming chemistry with everything dissolved. There is no resin. Each intermediate is a real, isolable compound that can be purified by crystallisation or extraction before the next step.

That difference cuts both ways. The advantage is that purification happens along the way rather than only at the end, so errors are removed at the stage they occur instead of compounding, and reactions scale to quantities where filling a column with resin stops being economic. For short sequences made in large amounts, solution-phase can deliver a cleaner product at a lower cost per gram.

The disadvantage is that it does not scale with sequence length. Every step needs its own workup, solvent system and isolation, developed for that specific intermediate. There is no generic cycle to automate. Past roughly a dozen residues the method becomes impractical for most purposes, and long research peptides are not made this way.

Hybrid approaches

The two routes are not mutually exclusive, and industrial practice frequently combines them. In a convergent or fragment-condensation approach, short segments are built separately — often on resin, where the cycle is cheap — then cleaved, purified individually, and joined in solution. Because each fragment is purified before final assembly, deletion sequences from one fragment never travel into the finished chain.

Convergent routes are chosen when the target is long enough that linear SPPS gives a poor crude, or when a junction in the sequence is prone to a side reaction easier to control in solution. The trade-off is that joining two protected fragments is itself a coupling step, with its own efficiency, and the junction residue is the site most at risk of racemisation.

The impurity classes, and where each one comes from

Every impurity class in a synthetic peptide traces to a specific step. This is what makes the route informative rather than trivia — if you know how it was made, you know what to look for.

Deletions and truncations are not the same problem

A truncation is a chain that stopped. It is shorter, lighter and chemically quite different from the target, so both instruments see it easily and a preparative column separates it without much difficulty.

A deletion is missing exactly one residue from the middle and is otherwise correct — the same molecule minus one unit. Its behaviour on a reverse-phase column can be almost indistinguishable from the target's. Deletions are why purification is a separation problem rather than a filtration problem.

Racemisation is the impurity an instrument struggles to see

Amino acids are chiral. Under the activation conditions that make coupling fast, a proportion of residues can epimerise, producing a chain with the correct sequence and the correct mass but the wrong configuration at one position. Mass spectrometry cannot distinguish it — the mass is identical — and a standard reverse-phase separation may or may not resolve it into its own peak. This is the clearest example of why a purity figure is bounded by what the method can see.

The counter-ion is not in the purity calculation

When a peptide with basic residues comes off a trifluoroacetic acid cleavage and is purified in a TFA-containing gradient, it is isolated as its trifluoroacetate salt. That counter-ion can be a meaningful fraction of the dry mass in the vial. It is not counted against purity by a peptide-area HPLC method, because it is not a peptide and produces no peak in the region being integrated.

This is the most common source of confusion between two different numbers. Purity is the proportion of detected peptide that is the target. Net peptide content is the proportion of the vial contents that is peptide at all, with salt and residual water making up the rest.

Crude versus purified, and why the distinction is load-bearing

Crude peptide is what comes off the resin after cleavage, before any separation. Short, well-behaved sequences give good crudes; long or aggregation-prone sequences give poor ones.

Purified peptide is the fraction collected off a preparative column, where the operator chose where to start and stop collecting. That choice is the whole purification. Collect a wide window and you recover more material at lower purity; collect a narrow window centred on the peak and you get higher purity at lower yield. Nothing about the chemistry changed between those decisions — only the cut.

That is why crude and final purity are not comparable figures and should never appear as though they are. The longer treatment of how a released figure gets established is in the guide on how research peptide purity is verified.

What preparative HPLC removes, and what it does not

Preparative reverse-phase HPLC is the workhorse of peptide purification. The crude is loaded onto a column, a solvent gradient carries components through at different speeds according to how strongly each interacts with the stationary phase, and fractions are collected as they elute. It separates on one axis: relative hydrophobicity.

That axis handles a great deal: truncations, retained protecting groups and most side-reaction products differ enough in hydrophobicity to separate cleanly. It handles some things poorly — a single-residue deletion may co-elute with the target, and a diastereomer frequently does. And some things not at all: the counter-ion is carried through rather than removed by a standard TFA gradient.

So a purified peptide is not one from which every non-target species has been removed. It is one from which species separable on that column, under that gradient, have been separated — and the remaining impurities are, by definition, the ones most similar to the target. That is the reason identity confirmation by mass is not optional, and the reason a purity figure has to be read together with its method.

Reading the synthesis off a certificate

A certificate does not usually state the synthetic route, and it does not need to. What it carries, if complete, is the set of fields that let you reason about it.

• The purity method. Reverse-phase HPLC with column, gradient and detection wavelength stated. Without it the figure cannot be compared to anything.
• The identity result. Observed mass against theoretical mass for the sequence — what rules out a very pure sample of the wrong compound.
• The lot number. Yield and impurity profile vary run to run, which is why analysis is performed per batch rather than once per product.
• Net peptide content where reported. The counter-ion and residual water question, separated from the purity question.
• The report date. Oxidation can progress after analysis, so the document describes the material as measured on that date.

The field-by-field walkthrough is in the guide on how to read a certificate of analysis, and who performed the analysis is covered in the guide on third-party testing and independent verification.

Three lots, and what to look for on each

The reasoning above is easier to apply against real documents. These are three released lots with published certificates, each link opening that lot's own record rather than a product-level document.

A blend is worth a note. The milligram figure on a blend vial is the total peptide content across the vial, not the amount of any single component. Each component was synthesised and purified separately before blending, so the specification applies per component. The two blends are compared in the guide on GLOW and KLOW.

Red flags in a synthesis or purity claim

• A purity percentage with no method beside it. The figure is a function of the column, gradient and detection wavelength. Without them it is not comparable to anything.
• Crude and final purity used interchangeably. They are different measurements at different stages.
• "Purity" and "net peptide content" treated as one figure. One is the proportion of detected peptide that is the target; the other is how much of the vial is peptide at all.
• A purity figure quoted for a product rather than a lot. Synthesis is a batch process and the impurity profile varies between runs.
• A single chromatogram presented for a whole catalogue. One separation describes one sample.
• A purity claim expressed as typical or average. An average tolerates lots beneath it. A floor is the number every released lot has to clear.
• Impossibly round figures. Real integration produces uneven values, not a column of identical round numbers.
• Silence on counter-ion and salt form. Not always disclosed, but a supplier who cannot answer when asked has told you something.

How this is handled at Glow

Every released lot is analysed by an independent laboratory — Freedom Diagnostics, named on the certificates themselves — using reverse-phase HPLC for purity and mass spectrometry for identity. The published specification is a floor of ≥99.2%: the number every released lot must clear, not a value some lots reach. For blends it applies per component.

The records are public. Every released lot's certificate is reachable from the quality and COA directory without an account or a request, and the QR code on a vial opens that lot's record. Where a lot's report includes additional attributes such as endotoxin, those results appear on that lot's certificate and apply to that lot alone.

Two limits belong in the same paragraph as the strengths. Analytical results are specific to the lot and the method used, so a figure from a different method is not directly comparable. And the certificate describes the material as analysed on the report date; storage and handling after that point sit outside what any certificate can speak to. The full catalogue is in the research peptide catalogue.

Frequently asked questions

What is the difference between SPPS and LPPS?

In solid-phase peptide synthesis the growing chain stays anchored to an insoluble resin bead, so excess reagents and by-products are washed away after each step. In liquid-phase, or solution-phase, synthesis everything is dissolved and each intermediate is isolated and purified on its own. Solid-phase is faster, automatable and practical for long sequences. Solution-phase suits short sequences at large scale. Many industrial routes combine both, building fragments on resin and joining them in solution.

What are the most common impurities in synthetic peptides?

Deletion sequences are the most common and the most difficult: a chain missing one internal residue because a coupling step did not finish. Truncations, where the chain stopped growing, are easier to separate. Beyond those, expect diastereomers from racemisation, oxidation products at methionine, cysteine and tryptophan, chains still carrying a side-chain protecting group, residual scavengers from the cleavage cocktail, and counter-ion paired with the peptide's basic groups.

Does preparative HPLC remove all impurities?

No. Preparative reverse-phase HPLC separates on relative hydrophobicity under the conditions used, which handles truncations and most side products well. It struggles with species chemically closest to the target: a single-residue deletion can co-elute, and a diastereomer from racemisation frequently does. Counter-ion is not removed by a standard gradient at all; changing the salt form is a separate operation. This is why identity confirmation by mass is run alongside purity rather than instead of it.

Why does the synthesis method affect the purity figure?

The route determines which impurities exist, and a purity figure counts only what the method detects. Fmoc and Boc strategies expose the chain to different conditions and produce different side-product profiles. A convergent route purifies fragments before assembly, so deletions from one fragment never reach the final chain. And because purity is reported as target peak area against total detected peak area, a species the detector cannot see is not in the calculation.

Is purity the same as net peptide content?

No, and confusing the two is common. Purity is the proportion of detected peptide that is the target compound, reported by HPLC under a stated method. Net peptide content is the proportion of the vial's contents that is peptide at all, with counter-ion such as trifluoroacetate and residual water making up the remainder. A peptide can be high on one figure and unremarkable on the other. A complete certificate reports them separately rather than collapsing them into one number.

More research articles · Browse research peptides